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Transcriptomic technologies are constantly changing and improving, resulting in an ever
increasing understanding of gene expression in health and disease. These technologies
have been used to investigate the pathological changes occurring in the joints of
rheumatoid arthritis patients, leading to discoveries of disease mechanisms, and novel
potential therapeutic targets. Microarrays were initially used on both whole tissue and
cell subsets to investigate research questions, with bulk RNA sequencing allowing for
further elaboration of these findings. A key example is the classification of pathotypes in
rheumatoid arthritis using RNA sequencing that had previously been discovered using
microarray and histology. Single-cell sequencing has now delivered a step change in
understanding of the diversity and function of subpopulations of cells, in particular
synovial fibroblasts. Future technologies, such as high resolution spatial transcriptomics,
will enable step changes integrating single cell transcriptomic and geographic data to
provide an integrated understanding of synovial pathology.
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INTRODUCTION
Research into transcriptomic changes in the diseased synovium in rheumatoid arthritis (RA) has
significantly enhanced our understanding of disease pathogenesis. This review details the research
pathway taken to study gene expression in the synovium, including methods for synovial cell
isolation, and analysis of tissue and cells by microarray and RNA-sequencing technologies. The
progression of gene expression technologies which have increased our understanding of disease
processes will be described, with a focus on understanding fibroblast populations, on which new
transcriptomic technologies have had their most profound impact.
The synovium is a thin tissue lining the interior of the fibrous capsule, enclosing diarthroidal
joints, and facilitating the normal function of the joint (1). In healthy, uninflamed joints the
synovium produces compounds such as hyaluronate and lubricin. These are vital components of
synovial fluid which fills the joint space and provides lubrication to aid load-bearing and flexion
without damage to the cartilage and underlying bone (1, 2). By contrast, the inflamed synovium in
RA is characterized by tissue hyperplasia and angiogenesis, accompanied by infiltration of multiple
leukocyte populations, most significantly including monocytic cells, T and B lymphocytes. The
latter frequently form organized aggregates that persist over time, releasing inflammatory cytokines
and chemokines, and contributing to autoantibody production while remaining resistant to the
normal processes of apoptosis and resolution that characterize acute inflammation (3, 4).
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Fibroblasts play key roles within the RA synovium both in
the regulation of leukocyte influx and efflux, and in damaging
cartilage and driving indirect damage to bone (5–11). In RA,
fibroblasts within the synovium become persistently activated,
resulting in reduced responses to apoptotic signals, increased
proliferation, production of proinflammatory molecules, such as
IL-6 and CCL5, and the release of matrix remodeling enzymes,
such as matrix metalloproteinase-3 (MMP-3) and MMP-9
(12–19). Consequently, the synovium develops an aggressive
phenotype, leading to inflammation and hyperplasia, causing
pain, and loss of function (17, 20). Whilst the role of fibroblasts
in supporting these processes has been described in vitro, our
knowledge of fibroblast heterogeneity and functions in vivo has
been limited to decades-old histological observations of synovial
microanatomy. This was dominated by the differing appearances
of lining layer cells, which undergo hyperplasia in RA and appear
to be continuous with destructive pannus tissue that damages
cartilage, and sublining cells that are located alongside leukocyte
infiltrates and synovial blood vessels. This heterogeneity led
to synovial fibroblasts being termed fibroblast-like synoviocytes
(FLS) historically, however recently developed transcriptomic
technologies, specifically single-cell sequencing, have allowed for
the recognition of subpopulations of fibroblasts. Understanding
these subpopulations and their differing functions has the
potential to open new doors for therapeutic intervention.
ISOLATING CELLS FROM SYNOVIAL
TISSUE
Studies are generally completed at two levels of resolution, from
either whole-tissue or individual cellular populations. Whilst
the methods for obtaining whole-tissue samples of synovium
are fairly standardized (arthroplasty or biopsy), the methods of
obtaining cellular populations are varied, which confounds the
results of downstream analyses.
Two main methods, the enzymatic digest method and the
explant-outgrowth method, are widely used to isolate and study
synovial cells, in particular synovial fibroblasts. The enzymatic
method of isolation focuses on disrupting the extracellular matrix
and adhesion of cells to this matrix to create a suspension of
synovial cells. However, a range of enzymes, concentrations,
and lengths of digestion have been used to achieve this, with
limited investigation of the efficacy of the isolation or the effect
of the digestion on marker expression and cellular viability.
This complicates interpretation when examining surface protein
expression or gene expression ex vivo, making it challenging to
compare between studies.
The explant outgrowth method is more consistent between
publications, possibly due to the relative simplicity of the
protocol. Small segments of synovial tissue are placed into tissue-
culture, allowing adherent cells to migrate out of the tissue and
begin proliferating (21, 22). After 7 days the remaining tissue is
removed and the cells are cultured. Whilst easier to implement
than the enzymatic digestion protocol, the explant-outgrowth
technique is not without its caveats. There is a significant risk of
selecting for synovial populations that proliferate rapidly and are
able to migrate out of the tissue, meaning that other populations
may not be accounted for.
To address the heterogeneity in isolation methods the
National Institutes of Health (NIH) Accelerating Medicines
Partnership (AMP, https://www.nih.gov/research-training/
accelerating-medicines-partnership-amp), a consortium of
research groups funded by government, industry, and non-profit
organizations, developed optimized protocols for the isolation of
cells from multiple tissues, including the synovium, alongside a
protocol for the cryopreservation of synovial tissue allowing for
later digestion, which aids in reducing batch effects (23). This
approach brings consistency to the field of synovial dissociation,
allowing for more robust comparisons between results from
different research groups.
WHOLE TISSUE APPROACHES TO
SYNOVIAL TISSUE ANALYSIS
Studies investigating gene expression in the synovium initially
took whole tissue approaches to assess broad, organ level
changes. Whilst this work serves a purpose with regards to
biomarker screening and understanding links between synovial
and systemic inflammation, it is difficult to determine which
specific cells are responsible for the changes in gene expression.
Furthermore, subtle yet relevant alterations in gene expression
amongst small cell populations are likely to bemasked by changes
in more dominant ones, meaning important mechanisms may
be missed.
INTERROGATING THE SYNOVIUM BY
GENE EXPRESSION ARRAY
Whilst the investigation of specific genes using PCR can be a
powerful tool for testing pre-existing hypotheses, the ability to
screen thousands of genes can extend gene expression analyses
into discovery-focussed approaches. The development of cDNA
microarray technology filled this niche. cDNA microarrays are
inert supports, such as glass slides, upon which probes are
printed or “grown” using masking techniques in spots, with each
spot containing probes for a single gene (24, 25). In the most
common platforms RNA is converted to cDNA before being
labeled with a fluorescent dye. The cDNA is then hybridized to
the probes in the microarray. After removing unbound RNA, the
fluorescence measured from each spot can be used to calculate
relative gene expression.
The strength of cDNA arrays is in the number of genes that
can be simultaneously screened. Lindberg et al. (26) used an
in-house generated microarray to investigate the expression of
16,164 genes in RA synovial tissue. The authors investigated
differences in gene expression between synovial biopsy material
obtained during arthroscopy and arthroplasty from several
different sites within each joint to quantify the variation in gene
expression dependent on the sampling procedure. Interestingly,
even when non-inflamed biopsy samples were excluded from
the analysis, a large number of differentially expressed genes
were found between biopsy samples from the same joint. Despite
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this finding, the authors were able to identify patient-specific
gene expression signatures, indicating that the variation imparted
by the biopsy site does not completely obscure the variation
between patients.
Several publications have investigated the contribution of
anatomical origin to the variance seen in fibroblast gene
expression. Chang et al. (27) and Rinn et al. (28) usedmicroarrays
to investigate the differences in gene expression between skin
fibroblasts isolated from different locations of the body. The
major determinant of differential expression between sites was
shown to be amongst genes encoding proteins involved in
cell development during embryogenesis. Fibroblasts isolated
from the same anatomical location in different donors showed
closer gene expression profiles than those from a different
anatomical location in the same donor (29). This indicates that
developmental pathways may impact more upon fibroblast gene
expression than inter-individual variation, as might be expected
for cells involved in tissue specific structural patterning.
Microarray platforms can be applied not only to whole tissue
but to any sample from which sufficient RNA can be isolated.
Microarrays have been used with laser capture microdissection, a
technique for isolating specific regions of tissue from histological
sections, to compare gene expression in the synovial lining layer
between RA and osteoarthritis (OA) samples (30). One hundred
ninety-seven genes were detected as differentially expressed
between the two diseases. Samples clustered according to disease,
indicating that the lining layer is significantly different in
phenotype between RA and OA. Additionally, the RA samples
could be sub-clustered into high- and low-inflammation samples,
a feature that was supported by similar high and low levels of
serum C-reactive protein or histological inflammation scores.
The concept of subclassifying RA samples on the basis of
gene expression has been explored by other investigators. van
der Pouw Kraan et al. (31) used hierarchical cluster analysis
of microarray data generated from the synovial tissue of RA
patients undergoing arthroplasty to find subgroups based on
differences in synovial gene expression. In concordance with
later work by Yoshida et al. (30), the samples clustered into
high and low inflammatory groups. The high inflammatory
group was characterized by high CD3D, IL2RG, and CD8
expression, suggesting that these differences were driven by
differential immune-cell infiltration into the synovium. However,
the investigators subsequently showed that synovial groupings
could be mapped onto the transcriptomes of synovial fibroblasts
cultured from the same tissues, demonstrating a link between
fibroblast, and leukocyte populations (32).
Microarrays can also be used to correlate gene expression
with response to therapy. This holds particular importance
as, without stratification, RA patient therapeutic responses are
characteristically <70%, even to targeted biologic agents. If gene
expression could inform which therapeutic regime is likely to
have the most effect, it would not only benefit patients but
also reduce the cost of care (33). One study used an in-house
developed microarray targeting 17,972 genes to measure gene
expression in the synovial tissue of 48 RA patients who responded
to therapy to varying degrees, and 14 non-responders. The
main source of variance in gene expression was the presence
or absence of inflammatory aggregates within the synovial
tissue, however no clear differences between responders or non-
responders were found (34). In a seminal paper, Dennis et al.
used microarrays to assess response to first anti-TNF therapy,
discovering modules of response corresponding to dominance
of different cell types (myeloid, fibroid, or lymphoid) that were
correlated to immunohistochemistry (35).
Whilst the data provided by microarrays has provided
insight into the pathogenesis of inflammatory synovial disease,
this technology is limited in the number of genes that can
be simultaneously assessed. With the development of RNA-
sequencing that allows measurement of the entire transcriptome,
attention has turned toward the use of these techniques and the
unique opportunities, and problems, they present.
RNA-SEQUENCING
RNA-sequencing (RNA-seq) offers significant advantages over
microarrays with regards to assessing gene expression, namely
not targeting a specific selection of genes. RNA-seq can measure
protein coding and non-coding genes, and even micro-RNAs,
increasing the utility of this tool. In addition, RNA-seq provides
data over a larger dynamic range with lower background noise
than microarray technology (36). Untargeted RNA-seq consists
of the isolation of RNA and conversion to a cDNA library, which
is then sequenced. Computational alignment to the genome or
transcriptome can then be performed, avoiding the need for
pre-selected targets.
Orange et al. (37) used bulk RNA-seq to investigate total
synovial gene expression in tandem with histology, with an
aim to subclassify RA. The samples could be clustered as
high- or low-inflammatory tissues along with an additional
mixed cluster. Six thousand five hundred eighty-two genes were
detected as differentially expressed between the clusters, with the
high inflammatory cluster expressing increased levels of genes
associated with immune related pathways. Investigation of key
histological variables in the tissue samples showed concordance
with the sequencing results, with the high-inflammatory samples
possessing high levels of immune cell infiltrate. Additionally, in
a longitudinal consortium study taking synovial biopsies at first
presentation of new RA, significant correlations were observed
between histological type, whole tissue bulk RNAseq-derived
gene clusters, and clinical response to first therapy (38, 39). This
powerful approach elegantly demonstrates the predictive value of
cellular gene clusters derived from whole tissue signatures.
SINGLE CELL APPROACHES TO
SYNOVIAL TISSUE ANALYSIS
Although bulk RNA-seq provides in-depth information on gene
expression in whole tissues or pre-defined populations of cells,
assumptionsmade regarding the number and type of cells present
may bias the results. Single cell RNA-sequencing (scRNA-seq)
can reduce this bias by allowing independent sequencing of
every cell within a tissue, or within a subset of cells (Figure 1).
The subsequent use of unsupervised clustering techniques to
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FIGURE 1 | Schematic illustrating bulk (A) vs. single cell (B) RNA sequencing. Bulk RNA sequencing requires researchers to preselect cellular populations or
sequence whole samples, whereas single cell RNA sequencing does not require pre-selection and can be used to identify cellular populations in an unbiased manner.
find related cells, as defined by gene expression, can confirm
the presence of previously defined populations or help in the
identification of unknown populations of cells. However, caveats
exist for readers of such papers: firstly, it is possible to over-cluster
the data, leading researchers to believe there are more discrete
populations present than actually exist. Secondly, multiple
dimensionality reduction techniques and clustering methods
exist, which can lead to different interpretations of the data, and
which should therefore be clearly stated by authors and noted by
readers. Thirdly, the depth of information obtained by scRNA-
seq can be limited by low amounts of starting RNA, meaning
that the absolute number of genes that can be recognized and
quantified is lower than that of bulk RNA-seq. To leverage
the strengths of this technique, both approaches are commonly
used in tandem to identify key subpopulations and then further
investigate gene expression.
Mizoguchi et al. (40) used a combined approach of
microarrays, bulk, and single-cell RNA-sequencing to identify
subsets of fibroblasts in synovial tissue from RA and OA
patients. CD45−CD31−CD146− cells were found to split into
seven populations by flow cytometric analysis of CD34, CD90,
PDPN, and CDH11 expression. However, following microarray
and bulk RNA-seq of these populations, clustering of the data
identified three populations in both datasets, CD34−CD90−,
CD34−CD90+, and CD34+. scRNA-seq was then used on a small
number of samples (2 RA and 2 OA) to confirm this finding. The
CD34−CD90+ population was expanded in RA compared to OA
samples, as measured by flow cytometry, possessed high RANKL
and low OPG expression, and was capable of differentiating
monocytes to osteoclasts in vitro suggesting a role in bone
regulation and damage. The CD34+ population expressed high
levels of IL-6, CXCL12, and CCL2, whereas the CD34−CD90−
population expressed high levels ofMMP1, MMP3, PRG4, HAS1,
and CD55. These findings indicate that the traditional split of
lining vs. sublining does not capture the full heterogeneity of
synovial fibroblast populations.
Unbiased single cell sequencing platforms have helped
our understanding of the true heterogeneity of fibroblast
subpopulations and therefore synovial pathology. Within the
NIH AMP consortium, the exploration of synovial fibroblast
subsets was extended through a combined investigation
of larger numbers of RA and OA samples using bulk and
scRNA-seq, and flow and mass-cytometry. Zhang et al.
(41) used canonical correlation analysis to integrate this
multimodal data from 51 RA and OA samples, facilitating
a linked transcriptomic and proteomic analysis of single
cells. In addition to defining the myeloid, T and B cell
subpopulations present in the RA synovium, this study
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identified four synovial fibroblast populations: a CD55+
lining layer population and three sublining populations
identified as CD34+, HLAhi, or DKK3+. With regards to
gene expression, the sublining populations showed greater
similarities with each other than with the lining population,
a feature reflected in the shared enrichment for extracellular
matrix related pathways within the sublining populations.
HLAhi synovial fibroblasts were the predominant source of
IL-6. When classifying RA samples on the basis of immune
infiltrate identified by histology, the HLAhi population
was expanded in leukocyte-rich synovium, hinting that
this population may be driving classical inflammation
within the synovium, whereas others, such as the CD55+
lining layer population, may be responsible for aspects of
cartilage destruction.
The function of individual synovial fibroblast populations
has been further explored using murine models of arthritis.
Croft et al. (42) used the serum transfer induced arthritis
model in combination with the deletion of fibroblast activation
protein-α (FAPα) expressing cells to interrogate the role
of synovial fibroblast subsets. FAPα is expressed on both
lining and sublining fibroblasts in RA, therefore offering a
mechanism for the global deletion of synovial fibroblasts
(42–45). The deletion of FAPα+ cells during arthritis led to
both a significant reduction in inflammation and accelerated
resolution. This was accompanied by reductions in synovial
cellularity, joint damage, and leukocyte infiltration, highlighting
that the changes observed were not solely due to a reduction
in the number of cells within the synovium. Bulk-sequencing
of sorted populations mirrored the findings of Zhang et al.
(41), with the largest differences being observed between the
lining layer and sublining layer (45). Further similarities existed
in the gene expression profile of these populations with the
FAPα+CD90+ cells expressing higher levels of chemokines
and cytokines, including IL-6, whereas the FAPα+CD90− cells
showed higher levels of RANKL and MMPs. The functional
behavior of these populations was confirmed by adoptive
transfer of the sorted populations into the joints of arthritic
mice. FAPα+CD90+ cells increased inflammation but not
joint damage, whereas the reverse was observed with the
FAPα+CD90− cells. Finally, scRNA-seq of murine synovial
fibroblasts revealed that five independent populations could
be found, one lining layer, three sublining, and an additional
cycling population.
FUTURE PREDICTIONS
The investigation of synovial fibroblasts provides an excellent
illustration of the power of single cell analyses. Our previous
knowledge was restricted to speculation based on anatomical
sub regions in the synovium and limited fibroblast surface
markers. For the first time investigators have been able to
identify and assign putative functions to individual fibroblast
subpopulations that were previously unknown using the power of
single cell sequencing. This provides exciting new opportunities
to understand the pathobiology of inflammatory arthritis, and to
target novel therapeutic approaches to fibroblast cells. Even the
field of lymphocyte biology, in which multiple cellular subsets
have already been identified, has been changed by single cell
analyses of synovial tissue, as in the recent identification of a
novel pro-inflammatory synovial T cell subpopulation in RA
assisted by mass cytometry (46). Techniques such as cellular
indexing of transcriptomes and epitopes by sequencing (CITE-
seq) and RNA expression and protein sequencing assay (REAP-
seq) are enabling the simultaneous resolution of transcriptomic
and proteomic data at an individual cell level (47, 48).
The challenge now is to recast previously published findings
into this new framework of individual subpopulations, and
to integrate isolated cell transcriptomic and proteomic data
with multiparameter platforms providing spatial proteomic and
transcriptomic data alongside established techniques such as
laser capture microdissection.
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